SCHEMBL8215440

SCHEMBL8215440

CNC(=O)Nc1ccc(-c2nc(N)cc(C(C)(C)S(=O)(=O)c3ccc(F)cc3)n2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.43
CA2 P00918 4/20 0.42
CA9 Q16790 4/20 0.42
CA12 O43570 3/20 0.42
CA1 P00915 3/20 0.42
CA4 P22748 1/20 0.42
CA7 P43166 1/20 0.42
TP53 P04637 1/20 0.41
PIK3CA P42336 3/20 0.41
MTOR P42345 3/20 0.41
PIK3CG P48736 2/20 0.41
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40
KDM1A O60341 1/20 0.40
FAAH O00519 1/20 0.39
MGLL Q99685 1/20 0.39
PTGS2 P35354 2/20 0.39
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8205334 0.92 PIK3CA (0.41) KMT2ACA2CA9PIK3CAMTOR
SCHEMBL8214031 0.90 ALDH1A1 (0.46) KMT2ACA2CA9CA12CA1
SCHEMBL8214334 0.90 KIF11 (0.49) CA2CA9CA12CA1CA4
SCHEMBL8205299 0.89 PIK3CD (0.48) KMT2ACA2CA9CA12CA1
SCHEMBL11925958 0.89 CA2 (0.46) KMT2ACA2CA9CA12CA1
SCHEMBL11925440 0.88 CA2 (0.42) KMT2ACA2CA9CA12CA1
SCHEMBL8214220 0.85 PIK3CA (0.48) KMT2APIK3CAMTORPIK3CGMEN1
SCHEMBL8204669 0.85 KMT2A (0.45) KMT2APIK3CAMTORPIK3CGMEN1
SCHEMBL8219083 0.83 NAMPT (0.40) KMT2ACA2CA9CA12CA1
SCHEMBL11925811 0.82 KIF11 (0.44) KMT2APIK3CAMTORPTGS2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008023159-A1 MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2008-02-28 WO disclosed